Healthcare Professionals

Video Resource Center

  • Actionable genomic information for accurate diagnosis for metastatic patients with diagnostic ambiguity
    1
  • Case Study: Diagnosing patient with Cancer of Unknown Primary (CUP)
    1
  • Unclear Diagnosis in Patients with Metastatic Disease
    1
  • CancerTYPE ID In the Clinic
    1
  • Comparison of Molecular Diagnostic Tests and Clinical Validation of CancerTYPE ID
    1

CancerType ID Indications for Use and Limitations

CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.